secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K
Filed at:   2026-01-02T23:59:59+00:00
Accession:  0001753926-26-000010
Event type: m_and_a
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pelthos Therapeutics acquires Xeglyze (abametapir) head lice treatment for $1.8M
--------------------------------------------------------------------------------

- Total purchase price $1.8M; $450K deposit paid Nov 20, 2025, $1.35M paid at closing Dec 23, 2025.
- Xeglyze is FDA-approved (Jul 2020) for head lice in patients 6 months+; single 10-minute application.
- No future milestone, royalty, or other payments owed to Hatchtech; worldwide commercialization rights.
- Pelthos plans to relaunch Xeglyze in first half of 2027.
- CEO Scott Plesha says acquisition aligns with strategy of commercializing innovative products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000175392626000010/0001753926-26-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000175392626000010/g085066_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-26-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer